Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays

Journal of Autoimmunity

Volumn 31, Issue 2, 2008, Pages 166-174

  Picha, Lefkothea ^a   Pakas, Ioannis ^a   Guialis, Apostolia ^b   Moutsopoulos, Haralampos M ^a   Vlachoyiannopoulos, Panayiotis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Antigenic source; Autoantibodies; Immunoblot; Systemic sclerosis (scleroderma)

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; FIBRILLARIN ANTIBODY; HISTONE 1 ANTIBODY; SMALL NUCLEOLAR RIBONUCLEOPROTEIN ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COUNTER IMMUNOELECTROPHORESIS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; METAPHASE CHROMOSOME; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

ADULT; AGE OF ONSET; ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; FEMALE; HELA CELLS; HUMANS; IMMUNOBLOTTING; LIVER; MALE; RATS; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 50549105056     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.07.001     Document Type: Article

References (79)

1. Gilliland B.C. Systemic sclerosis (scleroderma). (international edition). In: Isserbacher K.J., Braunwald E., Wilson J.D., Martin J.B., Fauci A.S., and Kasper H. (Eds). Harrison: principle of internal medicine. 13th ed. (1994), Mc Graw-Hill, New York 1665-1671
2. Medsger Jr. T.A. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: Mc Carthy D.J. (Ed). Arthritis and allied conditions (1989), Lee & Febiger, Philadelphia, PA 1118-1165
3. Steen V.D., Powell D.L., and Medsger T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31 (1988) 196-203
4. Harris M.L., and Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15 6 (2003) 778-784
5. Walker J.G., and Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 19 6 (2007) 580-591
6. Manoussakis M.N., Constantopoulos S.H., Gharavi A.E., and Moutsopoulos H.M. Pulmonary involvement in systemic sclerosis: association with anti-Scl 70 antibody and digital pitting. Chest 92 (1987) 509-513
7. Weiner E.S., Earnshaw W.C., Senthcal J.L., Bordwell B., Jhonson P., and Rothfield N.F. Clinical associations of anti-centromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 31 (1988) 378-385
8. Tan E.M. Autoantibodies to nuclear antigens (ANA): their immunology and medicine. Adv Immunol 33 (1982) 167-240
9. Ernshaw W.C., Bordwell B., Marino C., and Rothfield N.F. Three human chromosomal autoantigens are recognized by sera from patients with anticentromere antibodies. J Clin Invest 77 (1986) 426-430
10. Akbarali Y., Matousek-Ronck J., Hunt L., Sraudt L., Reichlin M., Guthridge J., et al. Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies. J Autoimmun 27 4 (2006) 272-280
11. Wang J.C. DNA topoisomerases. Annu Rev Biochem 54 (1985) 665-697
12. D'Arpa P., White-Cooper H., Cleveland D.W., Rothfield N.F., and Earnshaw W.C. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum 33 10 (1990) 1501-1511
13. Bizzaro N., Tonutti E., Villalta D., Bassetti D., Tozzoli R., Manoni F., et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. Clin Chem 46 10 (2000) 1681-1685
14. Whyte J., Earnshaw W.C., Champoux J.J., Parker L.H., Stewart L., Hall N.D., et al. Detection of anti-topoisomerase antibodies using a full length human topoisomerase I recombinant protein purified from a bacullovirus expression system. Clin Exp Immunol 100 (1995) 214-218
15. Hildebrandt S., Weiner E., Senucal J.L., Noell G.S., Earnshaw W.C., and Rothfield N.F. Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunoasorbent assay. Clin Immunol Immunopathol 57 (1990) 399-410
16. Reichlin M., Maddison P.J., Targoff I., Bunch T., Arnett F., Sharp G., et al. Antibodies to nuclear/nucleolar antigen in patients with polymyocitis overlap syndrome. J Clin Immunol 4 (1984) 40-44
17. Van Eenennaam H., Vogelzangs J., Bisschops L., Boome L., Seelig H., Renz M., et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 130 (2002) 532-540
18. Reimer G., Steen V.D., Penning C.A., Medsger Jr. T.A., and Tan E.M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 31 (1988) 525-532
19. 3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35 (1992) 95-100
20. Yang J.M., Hildebrandt B., Luderschmidt C., and Pollard M. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar rnp complex. Arthritis Rheum 48 1 (2003) 210-217
21. Kipnis R.J., Craft J., and Hardin J.A. The autoantibodies of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assay. Arthritis Rheum 33 9 (1990) 1431-1437
22. Kasturi K.N., Hakeyana A., Spiera H., and Bona C.A. Anti-fibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med 181 (1995) 1027-1036
23. 3 and Th(7-2) ribonucleoprotrins in patients' sera using riboprobes. J Immunol Methods 169 (1994) 173-182
24. Oddis C.V., Okano Y., Rudert W.A., Trucco M., Duquesnoy R.J., and Medsger Jr. T.A. Serum autoantibody to the nucleolar antigen PM-Scl. Arthritis Rheum 35 10 (1992) 1211-1217
25. Malher M., and Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex. Clinical, genetic and diagnostic insights. Autoimmun Rev 6 7 (2007) 432-437
26. Okano Y., and Medsger Jr. T.A. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 35 (1990) 39-100
27. Yamane K., Ihn H., Kubo M., Kuwana M., Asano Y., Yazawa N., et al. Antibodies to Th/To ribonucleoporotein in patients with localized scleroderma. Rheumatology 40 (2001) 683-686
28. Imai H., Fritzler M.J., Neri R., Bombardieri S., Tan E.M., and Chan E.K.L. Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Mol Biol Rep 19 (1994) 115-124
29. Ulanet D., Wigley F., Gelber A., and Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 49 1 (2003) 85-92
30. Reimer G., Rose K.M., Sheer K., and Tan E.M. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 79 (1987) 65-72
31. Kuwana M., Kaburaki J., Okano Y., Tojo T., and Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91 (1993) 1399-1404
32. Yamasaki Y., Honkannen-Scott M., Hernandez L., Ikeda K., Barker T., Bubb M., et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54 9 (2006) 3051-3056
33. Bardoni A., Rossi P., Salvini R., Bobbio-Palaviccini F., Caporali R., and Montecucco C. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 21 (2003) 301-306
34. Kuwana M., Okano Y., Pandey J., Silver R., Fertig N., and Medsger T. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody. Arthritis Rheum 52 8 (2005) 2425-2432
35. Sato S., Ihin H., Kikuchi K., and Takehara K. Antihistone antibodies in systemic sclerosis. Arthritis Rheum 37 3 (1994) 391-394
36. Fujimoto M., Sato S., Ihn H., Kikuchi K., Tamaki K., and Takehara K. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Arthritis Rheum 38 7 (1995) 985-989
37. Fujimoto M., Sato S., Kikuchi K., Tamaki K., and Takehara K. Antiubiquitin antibody in localized and systemic scleroderma. Ann Rheum Dis 55 (1996) 399-402
38. Asano Y., Hironobu I., Yamane K., Kubo M., and Tamaki K. The prevalence and clinical significance of anti-U1RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 120 (2003) 204-210
39. Kubo M., Ihn H., Kuwana M., Asano Y., Tamaki T., Yamane K., et al. Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap. Rheumatology 41 (2002) 531-534
40. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis); classification, subsets and pathogenesis. J Rheumatol 15 (1988) 202-205
41. Bernstein R.M., Bun C.C., and Hughes G.R.V. Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. Ann Rheum Dis 41 (1982) 554-555
42. Choi Y.D., and Dreyfus G. Isolation of the heterogeneous nuclear RNA-ribonucleoprotein complex (hn RNP): A unique supramolecular assembly. Proc Natl Acad Sci U S A 81 (1984) 7471-7475
43. 4. Nature 227 (1970) 680-685
44. Towbin H., Staehelin T., and Gordon G. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and applications. Proc Natl Acad Sci U S A 76 (1979) 4350-4354
45. Berezney R. Large scale isolation of nuclear membrane from bovine liver. Methods Cell Biol 7 (1974) 205-228
46. Berezney R., and Coffey D.S. Nuclear matrix isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol 73 (1977) 616-637
47. Wittemann B., Neuer G., Michels H., Truckenbrodt H., and Bautz F.A. Autoantibodies to non-histone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 33 9 (1990) 1378-1383
48. Masden M.P.F., and Laemmli U.K. Metaphase chromosome structure: evidence for a radial loop model. Cell 17 (1979) 849-858
49. 2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. J Clin Invest 81 (1988) 1716-1724
50. Petterson I., Hinterberger M., Tsunejo M., Gottlieb E., and Steitz J.A. The structure of mammalian small nuclear ribonucleoproteins. J Biol Chem 259 (1984) 5907-5914
51. Merill C.R., Goldman D., Sedman S.A., and Ebert M.H. Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science 211 (1981) 1437-1438
52. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980) 581-590
53. Vlachoyiannopoulos P.G., Dafni U.G., Pakas I., Spyropoulou-Vlachou M., Stavropoulos-Giokas C., and Moutsopoulos H.M. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 59 (2000) 359-367
54. Steen V., and Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 (2003) 516-522
55. de Rooij D.J., van de Putte L.B., Habets W.J., Verbeek A.L., and van Venroij W.J. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serologic associations in rheumatic diseases. Scand J Rheumatol 17 (1988) 353-364
56. Catoggio L.J., Bernstein R.M., Black C.M., Hughs G.R., and Maddison P.J. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 42 (1983) 23-27
57. Reveille J.D., and Solomon D.H. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49 (2003) 399-412
58. van Venrooij W.J., Stapel S.O., Houben H., Habets W.J., Kallenberg C.G., Penner E., et al. Scl-86 a marker antigen for diffuse scleroderma. J Clin Invest 75 (1985) 1053-1060
59. Guldner H.H., Szostecki C., Vosberg H.P., Lakomek H.J., Penner E., Bautz F.A., et al. Scl-70 autoantibodies for scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma 94 (1986) 132-138
60. Tamby M., Servettaz A., Guilpain P., Tamas N., Berezne A., Batteux F., et al. Immunoblotting on Hep-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis. Clin Immunol 123 (2007) 82-88
61. McHugh N.J., Whyte J., Arlett C., Briggs D.C., Stephens C.O., Olsen N.J., et al. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 96 (1994) 267-274
62. Vlachoyiannopoulos P.G., Drosos A.A., Wilk A., and Moutsopoulos H.M. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32 (1993) 297-301
63. Iwai T., Muro M., Sugimoto K., Matsumoto Y., and Ohashi M. Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. Clin Exp Immunol 105 (1996) 285-290
64. Bernstein R.M., Steigerwald J.C., and Tan E.M. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48 (1982) 43-51
65. 3 ribonucleoprotein particle reveal sequence available for base pairing with pre-rRNA. Mol Cell Biol 7 (1987) 2899-2913
66. 3RNP particle. Arthritis Rheum 30 7 (1987) 793-800
67. Garcia J., Osuna M., Castrejon F., Enriquez L., Reyes P., and Hermosillo J. Methods to detect antifibrillarin antibodies in patients with systemic sclerosis (SSc): a comparison. J Clin Lab Anal 18 (2004) 19-26
68. Kurzhals G., Meurer M., Krieg T., and Reimer G. Clinical association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated telangiectasia. J Am Acad Dermatol 23 (1990) 832-836
69. Mchalen C.A., and Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24 5 (1995) 323-358
70. Gioud M., Aitkaci A., and Monier J.C. Histone antibodies in systemic lupus erythematosus: a possible diagnostic tool. Arthritis Rheum 25 (1982) 407-413
71. Kohda S., Kanayama Y., Okamura M., Amatsu K., Negoro N., Takeda T., et al. Clinical significance of antibodies to histones in systemic lupus erythematosus sera. J Rheumatol 16 (1989) 24-28
72. Ostensen M., Fredriksen K., Kass E., and Rekvig O.P. Identification of antihistone antibodies in subsets of juvenile chronic arthritis. Ann Rheum Dis 48 (1989) 114-117
73. Kubo M., Ihn H., Yazawa N., Sato S., Kikuchi K., and Tamaki K. Prevalence and antigen specificity of AHA in patients with polymyositis/dermatomyositis. J Invest Dermatol 112 (1999) 711-715
74. Kuwana M., Okano Y., Kaburaki J., Tojo T., and Medsger Jr. T.A. Racial differences in the distribution of systemic sclerosis related serum antinuclear antibodies. Arthritis Rheum 37 (1994) 902-906
75. Muro Y., Yamada T., Himeno M., and Sugimoto K. cDNA cloning of a novel autoantigen targeted by a minor subset of anti-centromere antibodies. Clin Exp Immunol 111 (1998) 372-376
76. Kubo M., Ihn H., Yamane K., Yazawa N., and Tanaki K. Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin. Clin Exp Immunol 126 (2001) 339-344
77. Vlachogiannopoulos P.G., Guialis A., Tzioufas A.G., and Moutsopoulos H.M. Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol 35 (1996) 534-541
78. Manoussakis M.N., Kistis K.G., Liu X., Aidinis V., Guialis A., and Moutsopoulos H.M. Detection of anti-Ro(SSA) antibodies in autoimmune diseases: comparison of five methods. Br J Rheumatol 32 (1993) 449-455
79. Fujimoto M., Shomozuma M., Yazawa N., Kubo M., Ihn H., Sato S., et al. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SSA autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 56 (1997) 667-670